AA Pipeline Watch: Sun Pharma’s Deuruxolitinib Performs Well in New Phase 3 Data
Twice-daily dosing of deuruxolitinib resulted in significant hair regrowth for adults with moderate-to-severe alopecia areata (AA), and these improvements were visible as early as 12 weeks and lasted throughout the 24-week study, according to the Phase 3 THRIVE-AA2 trial. The new results, presented as a late breaker at Maui Derm 2024, are consistent with earlier data on the Janus kinase […]